What we are building
A single-use cartridge that identifies the pathogen and its resistance determinants from one sample, in one workflow, without a thermal cycler or a laboratory.
Research path · Developed on our own account
One test. Many pathogens. Their resistance genes.
We are developing a portable CRISPR platform that unites amplification, detection and visual readout in a single equipment-light workflow — designed to identify priority bacterial pathogens and their resistance genes from one sample.
Development stage · Design targets, not verified performance · Founded 2026
Hyderabad, Telangana, India
Research is what we are building for ourselves · Services is what we build for you
This page describes technology Amplera is developing on its own account. It is not a service offering, and nothing on it is available to purchase today. If you are looking for assay development, validation or regulatory work, see Services.
Who is developing this
A molecular diagnostics technology company.
Amplera Biosciences is a molecular diagnostics technology company founded in 2026 in Hyderabad, India. We develop CRISPR detection, isothermal amplification and multiplex PCR technologies, and have delivered a validated 4-plex real-time PCR panel to a commercial partner.
This platform is developed on our own account, not under contract.
Where we are
Development stage
The underlying chemistries — isothermal amplification, CRISPR detection and lateral flow — are established. Our contribution is uniting them into one validated, multiplexed, point-of-care chassis. That integration is in active analytical validation.
Programme stage
Concept▸
Feasibility▸
Analytical validation▸
Clinical evaluation▸
Regulatory▸
Launch
The problem
The first dose is a guess.
When a patient presents with a serious infection, treatment starts before anyone knows what is causing it — or whether the drug will work. Culture and susceptibility testing take one to three days. That gap is where resistance spreads.
Design targets
Design targets, not verified performance.
• Result in under 30 minutes
• Pathogen and resistance-gene panel from one sample
• No instrument required
• A reagent cost that supports use in public health programs
Why it is defensible
Multiplexing is the technical leap.
Multiplex by design
Powered by OdigOS guide design, the chassis is built to detect several priority pathogens in one reaction. Multiplexing is the technical leap over singleplex CRISPR detection.
Resistance-gene calling
Simultaneous readout of major resistance determinants — carbapenemase genes and extended-spectrum beta-lactamase genes — to support antimicrobial stewardship.
Speed that changes a decision
Fast enough to guide the first antibiotic dose rather than confirm it afterward.
Equipment-light
Isothermal chemistry and a visual strip remove the thermal cycler and the laboratory.
An expandable chassis
New pathogens and resistance genes are added by redesigning guides and strip lines, not by rebuilding the assay.
Where it is intended to be used
Primary health centres, district hospitals, intensive care and emergency settings, diagnostic laboratories, military and NGO field units, and national public health programs.
Target pathogens
Panel design is guided by the WHO Bacterial Priority Pathogens List.
Target pathogens
Our first panel is designed around the WHO Bacterial Priority Pathogens List, focusing on clinically important bacteria responsible for severe infections and antimicrobial resistance. The initial panel targets:
Escherichia coliKlebsiella pneumoniaePseudomonas aeruginosaAcinetobacter baumanniiStaphylococcus aureus
Resistance gene panel
Alongside pathogen identification, the platform is being designed to detect major antimicrobial resistance determinants, including:
Carbapenemases: blaNDMblaKPCblaOXA-48-likeblaVIMblaIMPESBL: blaCTX-MMethicillin: mecA / mecCVancomycin: vanA / vanB (expandable)
This combination enables simultaneous identification of the infecting pathogen and its key resistance markers from a single sample, supporting faster evidence-based antimicrobial therapy.
Partner with us or fund this work
We work with collaborators, programs and funders on this platform.
We work with clinical collaborators, public health programs, research funders and investors on this platform. If your interest is in the platform rather than in a development program, we would like to hear from you.
Clinical and field collaborators
Sites for analytical and clinical evaluation on real specimens.
Research funders and public health programs
Grant-funded development, co-development, or evaluation within an existing program.
Investors
Non-dilutive and equity funding toward regulatory submission and manufacture.